Study S000932

A Multi-centre, Open-label, Parallel-group Trial Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

ClinicalTrials.gov record

Registration

Registration: NCT02210871
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 44
Start: 2014-08-07
Primary completion: 2015-06-03
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Hepatic Impaired
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1149-3924; EUDRACT_NUMBER:2009-011673-33; NIH:2009

Registered primary outcomes

Area under the semaglutide plasma concentration-time curve [Day 1 - day 36]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025186	Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Jensen L, Diabetes, obesity & metabolism	2018	Other trial	PMID 29205786 DOI	cites ClinicalTrials.gov:NCT02210871; registry reference RESULT:29205786